[Federal Register Volume 87, Number 210 (Tuesday, November 1, 2022)]
[Notices]
[Pages 65847-65849]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23759]


-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2022-0045]


Qualification of Drivers; Exemption Applications; Epilepsy and 
Seizure Disorders

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), Department 
of Transportation (DOT).

ACTION: Notice of applications for exemption; request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 13 individuals 
for an exemption from the prohibition in the Federal Motor Carrier 
Safety Regulations (FMCSRs) against persons with a clinical diagnosis 
of epilepsy or any other condition that is likely to cause a loss of 
consciousness or any loss of ability to control a commercial motor 
vehicle (CMV) to drive in interstate commerce. If granted, the 
exemptions would enable these individuals who have had one or more 
seizures and are taking anti-seizure medication to operate CMVs in 
interstate commerce.

DATES: Comments must be received on or before December 1, 2022.

ADDRESSES: You may submit comments identified by the Federal Docket 
Management System Docket No. FMCSA-2022-0045 using any of the following 
methods:
     Federal eRulemaking Portal: Go to www.regulations.gov/, 
insert the docket number, FMCSA-2022-0045, in the keyword box, and 
click ``Search.'' Next, sort the results by ``Posted (Newer-Older),'' 
choose the first notice listed, and click on the ``Comment'' button. 
Follow the online instructions for submitting comments.
     Mail: Dockets Operations; U.S. Department of 
Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, 
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140, 
1200 New Jersey Avenue SE, Washington, DC 20590-0001 between 9 a.m. and 
5 p.m., ET, Monday through Friday, except Federal holidays.
     Fax: (202) 493-2251.
    To avoid duplication, please use only one of these four methods. 
See the ``Public Participation'' portion of the SUPPLEMENTARY 
INFORMATION section for instructions on submitting comments.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, 
Medical Programs Division, (202) 366-4001, [email protected], FMCSA, 
DOT,

[[Page 65848]]

1200 New Jersey Avenue SE, Room W64-224, Washington, DC 20590-0001. 
Office hours are 8:30 a.m. to 5 p.m., ET, Monday through Friday, except 
Federal holidays. If you have questions regarding viewing or submitting 
material to the docket, contact Dockets Operations, (202) 366-9826.

SUPPLEMENTARY INFORMATION:

I. Public Participation

A. Submitting Comments

    If you submit a comment, please include the docket number for this 
notice (Docket No. FMCSA-2022-0045), indicate the specific section of 
this document to which each comment applies, and provide a reason for 
each suggestion or recommendation. You may submit your comments and 
material online or by fax, mail, or hand delivery, but please use only 
one of these means. FMCSA recommends that you include your name and a 
mailing address, an email address, or a phone number in the body of 
your document so that FMCSA can contact you if there are questions 
regarding your submission.
    To submit your comment online, go to www.regulations.gov/docket?D=FMCSA-2022-0045. Next, sort the results by ``Posted (Newer-
Older),'' choose the first notice listed, click the ``Comment'' button, 
and type your comment into the text box on the following screen. Choose 
whether you are submitting your comment as an individual or on behalf 
of a third party and then submit.
    If you submit your comments by mail or hand delivery, submit them 
in an unbound format, no larger than 8\1/2\ by 11 inches, suitable for 
copying and electronic filing. If you submit comments by mail and would 
like to know that they reached the facility, please enclose a stamped, 
self-addressed postcard or envelope.
    FMCSA will consider all comments and material received during the 
comment period.

B. Viewing Comments

    To view comments go to www.regulations.gov. Insert the docket 
number, FMCSA-2022-0045, in the keyword box, and click ``Search.'' 
Next, sort the results by ``Posted (Newer-Older),'' choose the first 
notice listed, and click ``Browse Comments.'' If you do not have access 
to the internet, you may view the docket online by visiting Dockets 
Operations in Room W12-140 on the ground floor of the DOT West 
Building, 1200 New Jersey Avenue SE, Washington, DC 20590-0001, between 
9 a.m. and 5 p.m., ET, Monday through Friday, except Federal holidays. 
To be sure someone is there to help you, please call (202) 366-9317 or 
(202) 366-9826 before visiting Dockets Operations.

C. Privacy Act

    In accordance with 49 U.S.C. 31315(b)(6), DOT solicits comments 
from the public on the exemption request. DOT posts these comments, 
without edit, including any personal information the commenter 
provides, to www.regulations.gov. As described in the system of records 
notice (DOT/ALL-14 FDMS), which can be reviewed at www.dot.gov/privacy, 
the comments are searchable by the name of the submitter.

II. Background

    Under 49 U.S.C. 31136(e) and 31315(b), FMCSA may grant an exemption 
from the FMCSRs for no longer than a 5-year period if it finds such 
exemption would likely achieve a level of safety that is equivalent to, 
or greater than, the level that would be achieved absent such 
exemption. The statute also allows the Agency to renew exemptions at 
the end of the 5-year period. FMCSA grants medical exemptions from the 
FMCSRs for a 2-year period to align with the maximum duration of a 
driver's medical certification.
    The 13 individuals listed in this notice have requested an 
exemption from the epilepsy and seizure disorders prohibition in 49 CFR 
391.41(b)(8). Accordingly, the Agency will evaluate the qualifications 
of each applicant to determine whether granting the exemption will 
achieve the required level of safety mandated by statute.
    The physical qualification standard for drivers regarding epilepsy 
found in Sec.  391.41(b)(8) states that a person is physically 
qualified to drive a CMV if that person has no established medical 
history or clinical diagnosis of epilepsy or any other condition which 
is likely to cause the loss of consciousness or any loss of ability to 
control a CMV.
    In addition to the regulations, FMCSA has published advisory 
criteria \1\ to assist medical examiners (MEs) in determining whether 
drivers with certain medical conditions are qualified to operate a CMV 
in interstate commerce.
---------------------------------------------------------------------------

    \1\ These criteria may be found in APPENDIX A TO PART 391--
MEDICAL ADVISORY CRITERIA, section H. Epilepsy: Sec.  391.41(b)(8), 
paragraphs 3, 4, and 5, which is available on the internet at 
https://www.gpo.gov/fdsys/pkg/CFR-2015-title49-vol5/pdf/CFR-2015-title49-vol5-part391-appA.pdf.
---------------------------------------------------------------------------

    The criteria states that if an individual has had a sudden episode 
of a non-epileptic seizure or loss of consciousness of unknown cause 
that did not require anti-seizure medication, the decision whether that 
person's condition is likely to cause the loss of consciousness or loss 
of ability to control a CMV should be made on an individual basis by 
the ME in consultation with the treating physician. Before 
certification is considered, it is suggested that a 6-month waiting 
period elapse from the time of the episode. Following the waiting 
period, it is suggested that the individual have a complete 
neurological examination. If the results of the examination are 
negative and anti-seizure medication is not required, then the driver 
may be qualified.
    In those individual cases where a driver has had a seizure or an 
episode of loss of consciousness that resulted from a known medical 
condition (e.g., drug reaction, high temperature, acute infectious 
disease, dehydration, or acute metabolic disturbance), certification 
should be deferred until the driver has recovered fully from that 
condition, has no existing residual complications, and is not taking 
anti-seizure medication.
    Drivers who have a history of epilepsy/seizures, off anti-seizure 
medication and seizure-free for 10 years, may be qualified to operate a 
CMV in interstate commerce. Interstate drivers with a history of a 
single unprovoked seizure may be qualified to drive a CMV in interstate 
commerce if seizure-free and off anti-seizure medication for a 5-year 
period or more.
    As a result of MEs misinterpreting advisory criteria as regulation, 
numerous drivers have been prohibited from operating a CMV in 
interstate commerce based on the fact that they have had one or more 
seizures and are taking anti-seizure medication, rather than an 
individual analysis of their circumstances by a qualified ME based on 
the physical qualification standards and medical best practices.
    On January 15, 2013, FMCSA announced in a Notice of Final 
Disposition titled, ``Qualification of Drivers; Exemption Applications; 
Epilepsy and Seizure Disorders,'' (78 FR 3069), its decision to grant 
requests from 22 individuals for exemptions from the regulatory 
requirement that interstate CMV drivers have ``no established medical 
history or clinical diagnosis of epilepsy or any other condition which 
is likely to cause loss of consciousness or any loss of ability to 
control a CMV.'' Since that time, the Agency has published additional 
notices granting requests from individuals for exemptions from the 
regulatory requirement regarding epilepsy found in Sec.  391.41(b)(8).
    To be considered for an exemption from the epilepsy and seizure 
disorders

[[Page 65849]]

prohibition in Sec.  391.41(b)(8), applicants must meet the criteria in 
the 2007 recommendations of the Agency's Medical Expert Panel (78 FR 
3069).

III. Qualifications of Applicants

Ralph Bollman

    Mr. Bollman is a 57-year-old class CM license holder in 
Pennsylvania. He has a history of seizure disorder and has been seizure 
free since 1984. He takes anti-seizure medication with the dosage and 
frequency remaining the same since 1984. His physician states that he 
is supportive of Mr. Bollman receiving an exemption.

Diane Berggren

    Ms. Berggren is a 54-year-old class C license holder in Oregon. She 
has a history of epilepsy and has been seizure free since 2011. She 
takes anti-seizure medication with the dosage and frequency remaining 
the same since 2011. Her physician states that he is supportive of Ms. 
Berggren receiving an exemption.

Ryan Freedman

    Mr. Freedman is a 32-year-old chauffer license holder in Michigan. 
He has a history of seizure disorder and has been seizure free since 
2007. He takes anti-seizure medication with the dosage and frequency 
remaining the same since April 2019. His physician states that he is 
supportive of Mr. Freedman receiving an exemption.

Jared Friedman

    Mr. Friedman is a 30-year-old class D license holder in New York. 
He has a history of seizure disorder and has been seizure free since 
2002. He takes anti-seizure medication with the dosage and frequency 
remaining the same since May 2019. His physician states that he is 
supportive of Mr. Friedman receiving an exemption.

Jacob Higginbotham

    Mr. Higginbotham is a 23-year-old class C license holder in Nevada. 
He has a history of epilepsy and has been seizure free since 2012. He 
takes anti-seizure medication with the dosage and frequency remaining 
the same since 2012. His physician states that he is supportive of Mr. 
Higginbotham receiving an exemption.

Matthew Jacobson

    Mr. Jacobson is a 27-year-old class C license holder in 
Pennsylvania. He has a history of seizures and has been seizure free 
since 2013. He takes anti-seizure medication with the dosage and 
frequency remaining the same since 2016. His physician states that he 
is supportive of Mr. Jacobson receiving an exemption.

Keith Maat

    Mr. Maat is a 37-year-old class C license holder in Kansas. He has 
a history of partial seizures evolving to secondary generalized 
seizures disorder and has been seizure free since 2011. He takes anti-
seizure medication with the dosage and frequency remaining the same 
since July 2019. His physician states that he is supportive of Mr. Maat 
receiving an exemption.

Matthew Raymond

    Mr. Raymond is a 34-year-old class B CDL holder in New York. He has 
a history of epilepsy and has been seizure free since 1999. He takes 
anti-seizure medication with the dosage and frequency remaining the 
same since 1999. His physician states that he is supportive of Mr. 
Raymond receiving an exemption.

Andrew Rieschick

    Mr. Rieschick is a 35-year-old class O license holder in Nebraska. 
He has a history of generalized tonic-clonic seizure disorder and has 
been seizure free since 2009. He takes anti-seizure medication with the 
dosage and frequency remaining the same since 2009. His physician 
states that he is supportive of Mr. Rieschick receiving an exemption.

Steven Schultz

    Mr. Schultz is a 34-year-old class DM license holder in Illinois. 
He has a history of seizures and has been seizure free since 2001. He 
takes anti-seizure medication with the dosage and frequency remaining 
the same since 2019. His physician states that he is supportive of Mr. 
Schultz receiving an exemption.

David Shively

    Mr. Shively is a 53-year-old class C license holder in Virginia. He 
has a history of seizures and has been seizure free since 1991. He 
takes anti-seizure medication with the dosage and frequency remaining 
the same since 1991. His physician states that he is supportive of Mr. 
Shively receiving an exemption.

Stephen St. Marthe

    Mr. St. Marthe is a 27-year-old class C license holder in North 
Carolina. He has a history of focal epilepsy with secondary 
generalization and has been seizure free since 2012. He takes anti-
seizure medication with the dosage and frequency remaining the same 
since 2014. His physician states that he is supportive of Mr. St. 
Marthe receiving an exemption.

Carsten Thode

    Mr. Thode is a 58-year-old class B CDL holder in Washington. He has 
a history of epilepsy and has been seizure free since 2014. He takes 
anti-seizure medication with the dosage and frequency remaining the 
same since 1990. His physician states that he is supportive of Mr. 
Thode receiving an exemption.

Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315(b), FMCSA requests 
public comment from all interested persons on the exemption petitions 
described in this notice. We will consider all comments received before 
the close of business on the closing date indicated under the DATES 
section of the notice.

Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2022-23759 Filed 10-31-22; 8:45 am]
BILLING CODE 4910-EX-P